Pharmacoeconomic review report : Ixekizumab (Taltz) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Common drug review clinical review report.

Common drug review clinical review report

Language:

English

Subjects (All):

Anti-inflammatory agents.

Physical Description:

1 online resource (vi, 24 pages) : illustrations.

Other Title:

Pharmacoeconomic review report Ixekizumab

Place of Publication:

Ottawa (ON) : CADTH, 2017.

Summary:

Ixekizumab (Taltz) is a humanized anti-interleukin (IL)-17A monoclonal antibody indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systematic therapy or phototherapy. The manufacturer is requesting listing of ixekizumab for adult patients in line with the indication. The recommended starting dose of ixekizumab is 160 mg, followed by 80 mg every two weeks for 12 weeks, and then 80 mg every four weeks. Ixekizumab is available as an 80 mg/1 mL pre-filled pen or pre-filled syringe, at a confidential price of $1,519. At the recommended dose, ixekizumab costs $27,342 in the first year of treatment and $19,747 in the each subsequent year. The manufacturer submitted a cost-utility analysis comparing ixekizumab and other biologic drugs available for the treatment of plaque psoriasis with standard of care (SoC, defined as combination treatment with methotrexate and phototherapy) in adult patients with moderate to severe plaque psoriasis who are candidates for systematic therapy. The analysis was based on a Markov state-transition model using a 45-year time horizon and undertaken from the perspective of the Canadian publicly funded health care system. The manufacturer reported that, compared with treatment with SoC, ixekizumab has an incremental cost-utility ratio (ICUR) of 113,023 per quality-adjusted life-year (QALY). When considering all comparators using a sequential analysis, subsequent entry biologic (SEB) infliximab is associated with the lowest ICUR (85,983 per QALY versus SoC), followed by ixekizumab ($346,946 per QALY versus SEB infliximab). All other comparator drugs were ruled out, as they were either dominated or extendedly dominated (i.e., they were more costly and less effective than one or more comparators).

Contents:

Abbreviations

Executive Summary

Information on the Pharmacoeconomic Submission

Summary of the manufacturer's pharmacoeconomic submission

Manufacturer's base case

Summary of manufacturer's sensitivity analyses

Limitations of manufacturer's submission

CADTH Common Drug Review Reanalyses

CADTH CDR Price-Reduction Analysis

Conclusions

APPENDIX 1. Cost Comparison

APPENDIX 2. Summary of Key Outcomes

APPENDIX 3. Additional Information

APPENDIX 4. Reviewer Worksheets

References.

Notes:

Description based on publisher supplied metadata and other sources.

Includes bibliographical references.